The first half of 2025 has been marked by a surge in strategic activity across the global healthcare, life sciences, and ...

Here, Michelle Tsai – chief operating officer at iOnctura – and Shane Olwill – chief development officer at Asgard ...

Onsite in Chicago at ASCO 2025, web editor Nicole Raleigh sat down with Dr Danny Nguyen, medical oncologist and haematologist ...

The Association of the British Pharmaceutical Industry (ABPI) has said that the new 10-year plan for the NHS has underplayed ...

The European Commission has cleared OD-L1 inhibitor Imfinzi (durvalumab) to treat adults with resectable muscle-invasive ...

A European pharma trade organisation has said that a new strategy launched by the EU to bolster the region's standing in life ...

Shares in Summit Therapeutics have risen sharply on a report that AstraZeneca is in discussions for a partnership focused on ...

Fruzaqla was licensed by Takeda from China's Hutchmed for $400 million upfront in 2023 and has also been approved in the US ...

A delay, as opposed to a firm stagnation, then, but one unfolding over several years. This applies not only to SMEs, but to ...

After months of preparation and a drip-feed of some of its key features, the UK government has raised the curtain on its new ...

Dizal will market sunvozertinib in the US under the Zegfrovy brand name, entering a market for EGFR inhibitors currently ...